DNTH
Dianthus Therapeutics, Inc.
$86.48
-3.15
(-3.51%)
Mkt Cap
3.61B
Volume
458,946
52W Range
16.64-96.5
Sector
Healthcare
Beta
0.09
EPS (TTM)
-0.11
P/E Ratio
-9.59
Revenue (TTM)
1.34M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.04M | 6.24M | 2.83M | 6.42M | 1.48M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (162.34M) | (84.97M) | (43.55M) | (28.48M) | (13.11M) | (74.94M) | (76.77M) | (57.52M) | (35.49M) | (9.43M) |
| EPS | -4.20 | -2.55 | -8.45 | -7.60 | -3.82 | -27.30 | -33.18 | -27.62 | -16.05 | -4.27 |
| Free Cash Flow | (129.27M) | (78.28M) | (36.97M) | (29.21M) | (60.80M) | (64.42M) | (60.16M) | (49.56M) | (24.46M) | (6.67M) |
| FCF / Share | -3.42 | -2.35 | -7.17 | -7.79 | -17.70 | -23.47 | -26.01 | -23.80 | -11.07 | -3.02 |
| Operating CF | (129.06M) | (78.18M) | (36.86M) | (29.07M) | (59.53M) | (64.02M) | (57.10M) | (41.89M) | (22.26M) | (6.53M) |
| Total Assets | 530.92M | 374.01M | 179.41M | 83.11M | 189.93M | 161.62M | 161.51M | 157.31M | 54.46M | 11.34M |
| Total Debt | 1.39M | 1.49M | 585,000 | 788,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 51.09M | 22.79M | 132.32M | 15.37M | 131.65M | 58.15M | 65.07M | 58.34M | 51.57M | 4.54M |
| Book Value | 493.40M | 352.48M | 168.87M | 73.66M | 172.67M | 143.91M | 141.19M | 145.65M | 50.32M | 9.04M |
| Return on Equity | -0.33 | -0.24 | -0.26 | -0.39 | -0.08 | -0.52 | -0.54 | -0.39 | -0.71 | -1.04 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 463,000 | 284,000 | 396,000 | 193,000 | 1.16M | 1.33M | 2.17M | 1.86M | 874,000 | 457,000 | 924,000 | 969,000 |
| Net Income | (40.83M) | 97.91M | (36.77M) | (31.63M) | (29.51M) | (28.44M) | (25.17M) | (17.61M) | (13.75M) | (10.56M) | (14.76M) | (11.14M) |
| EPS | -0.85 | 2.59 | -0.97 | -0.88 | -0.82 | -0.81 | -0.74 | -0.51 | -0.54 | -2.33 | -3.78 | -0.87 |
| Free Cash Flow | (28.87M) | (47.12M) | (30.56M) | (23.94M) | (27.65M) | (27.48M) | (21.29M) | (14.54M) | (14.97M) | (11.86M) | 1.64M | (4.75M) |
| FCF / Share | -0.60 | -1.25 | -0.81 | -0.67 | -0.77 | -0.78 | -0.62 | -0.42 | -0.58 | -2.62 | 0.42 | -1.25 |
| Operating CF | (28.86M) | (46.98M) | (30.55M) | (23.89M) | (27.63M) | (27.44M) | (21.27M) | (14.53M) | (14.94M) | (11.85M) | 1.50M | (4.73M) |
| Total Assets | 1.25B | 530.92M | 577.45M | 326.08M | 348.58M | 374.01M | 354.25M | 368.96M | 382.46M | 179.41M | 192.46M | 78.64M |
| Total Debt | 1.36M | 1.39M | 1.28M | 1.33M | 1.40M | 1.49M | 311,000 | 407,000 | 497,000 | 585,000 | 670,000 | 0 |
| Cash & Equiv | 627.67M | 51.09M | 55.98M | 13.24M | 10.12M | 22.79M | 33.67M | 314.17M | 329.72M | 132.32M | 157.28M | 62.63M |
| Book Value | 1.20B | 493.40M | 546.45M | 303.08M | 328.61M | 352.48M | 337.90M | 358.22M | 372.69M | 168.87M | 178.38M | 74.60M |
| Return on Equity | -0.03 | 0.20 | -0.07 | -0.10 | -0.09 | -0.08 | -0.07 | -0.05 | -0.04 | -0.06 | -0.08 | -0.15 |
DNTH News
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics CFO Sells $9.5 Million in Stock